Latest Conference Articles

At ADA 2021, John Buse, MD, PhD, says US Must Focus on Control of Obesity, Other T2D Risk Factors

At ADA 2021, John Buse, MD, PhD, says US Must Focus on Control of Obesity, Other T2D Risk Factors

June 30th 2021

ADA

Diabetes investigator John Buse, MD, PhD, says laser focus on reducing T2D risk factors is equally as important as using the next right drug against the disease.

Inside GRADE: Exec Committee Member John Buse, MD, PhD, Toplines Study Results, Calls for More Head-to-Head Research

Inside GRADE: Exec Committee Member John Buse, MD, PhD, Toplines Study Results, Calls for More Head-to-Head Research

June 30th 2021

ADA

Dr Buse’s in-depth review of the GRADE study is followed by a discussion of the keen need for more comparative research and the many new questions the results have raised about optimal T2D therapy.

ADA 2021: Baseline Insulin Use May not Impact Benefits of Finerenone in Patients with CKD, T2D

ADA 2021: Baseline Insulin Use May not Impact Benefits of Finerenone in Patients with CKD, T2D

June 29th 2021

ADA

ADA 2021. A subgroup analysis of the FIDELIO-DKD trial showed that finerenone use was beneficial regardless of baseline insulin use among patients with T2D and CKD.

GLP-1 RA, Insulin More Effective Second-line vs Sulfonylurea, DPP-4 Inhibitor for T2D

GLP-1 RA, Insulin More Effective Second-line vs Sulfonylurea, DPP-4 Inhibitor for T2D

June 29th 2021

ADA

Preliminary GRADE study results showed that liraglutide and insulin glargine added to metformin maintained A1c level in target range longer than glimepiride or sitagliptin.

ADA 2021: Use of Dapagliflozin Decreases Risk of Diabetes in Patients with CKD

ADA 2021: Use of Dapagliflozin Decreases Risk of Diabetes in Patients with CKD

June 29th 2021

ADA

ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.

ADA 2021: Renoprotection with Finerenone Consistent Regardless of SGLT2 Inhibitor Use

ADA 2021: Renoprotection with Finerenone Consistent Regardless of SGLT2 Inhibitor Use

June 26th 2021

ADA

ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not SGLT2 inhibitors were on board at study baseline.

ADA 2021: Study Finds Hospitalization Rates for New-onset Pediatric T2D Doubled During Pandemic

ADA 2021: Study Finds Hospitalization Rates for New-onset Pediatric T2D Doubled During Pandemic

June 25th 2021

ADA

Data released today at the American Diabetes Association 81st Scientific Sessions on a spike in new onset pediatric T2D at a single center during COVID-19 may signal much wider incidence.

ADA 2021 Symposia Focus on Health Disparities Exposed and Deepened by COVID-19 Pandemic

ADA 2021 Symposia Focus on Health Disparities Exposed and Deepened by COVID-19 Pandemic

June 25th 2021

ADA

Leading international diabetes researchers and clinicians will use the ADA's 81st annual Scientific Sessions as an ideal classroom to examine pandemic impact on diverse populations with diabetes.

ADA Virtual Meeting Will Offer 5 Symposia on Latest COVID-19 Findings

ADA Virtual Meeting Will Offer 5 Symposia on Latest COVID-19 Findings

June 24th 2021

ADA

The upcoming ADA virtual 81st Scientific Sessions will feature 5 sessions on the latest diabetes developments learned during the initial phases of the COVID-19 pandemic.

Clinical Trial Updates at the ADA Scientific Sessions 2021: A few primary care musts

Clinical Trial Updates at the ADA Scientific Sessions 2021: A few primary care musts

June 21st 2021

ADA

The American Diabetes Association 2021 Scientific Sessions run from June 25 to 29. This short slide show highlights 6 clinical trial updates that are a "must see" for primary care clinicians.